Beijing, China & South San Francisco, Calif., United States: IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034) This milestone further validates Biocytogen’s proprietary RenLite® antibody discovery platform, demonstrating its potential to advance innovative therapies for patients …
